Disease Information

General Information of the Disease (ID: DIS00310)

• Name: Idiopathic interstitial pneumonitis
• ICD: ICD-11: CB03

Type(s) of Resistant Mechanism of This Disease

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Silicon dioxide

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Long non-protein coding RNA (CHRF) [1]

• Resistant Disease: Pulmonary fibrosis [ICD-11: CB03.1]
• Molecule Alteration: Up-regulation; Interaction
• Resistant Drug: Silicon dioxide
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: THP-1 cells; Blood; Homo sapiens (Human); CVCL_0006
• In Vitro Model: MRC-5 cells; Lung; Homo sapiens (Human); CVCL_0440
• In Vitro Model: RAW 264.7 cells; Ascites; Mus musculus (Mouse); CVCL_0493
• In Vitro Model: NIH/3T3 cells; Whole embryo; Mus musculus (Mouse); CVCL_0594
• In Vivo Model: Pulmonary fibrosis miR-489 overexpression mouse model; Mus musculus
• Experiment for Molecule Alteration: Overexpression assay
• Experiment for Drug Resistance: Immunofluorescence assay
• Mechanism Description: CHRF-miR-489-MyD88 Smad3 signaling axis exerts key functions in silica-induced pulmonary fibrosis and may represent a therapeutic target for silicosis.

Investigative Drug(s) 1 drug(s) in total

Astragaloside IV

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: SIRT1 antisense RNA (SIRT1-AS) [2]

• Resistant Disease: Pulmonary fibrosis [ICD-11: CB03.1]
• Molecule Alteration: Down-regulation; Expression
• Resistant Drug: Astragaloside IV
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: RLE-6TN cells; Lung; Rattus norvegicus (Rat); CVCL_4693
• Experiment for Molecule Alteration: Overexpression assay; Knockdown assay
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: Collectively, sirt1 AS was critical for ASV-mediated inhibition of IPF progression and targeting of sirt1 AS by ASV could be a potential therapeutic approach for IPF.

References

• Ref 1: miR-489 inhibits silica-induced pulmonary fibrosis by targeting MyD88 and Smad3 and is negatively regulated by lncRNA CHRFSci Rep. 2016 Aug 10;6:30921. doi: 10.1038/srep30921.
• Ref 2: Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelial-mesenchymal transitionAging (Albany NY). 2020 Mar 6;12(5):4322-4336. doi: 10.18632/aging.102882. Epub 2020 Mar 6.